{‘She lacks little qualifications’: this US healthcare establishment prepares for Høeg's role at the Food and Drug Administration.

While the US continues making historic changes to its vaccination guidelines, one figure has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who rose to prominence by expressing skepticism about COVID-19 shots in the pandemic and has focused upon alleged deaths after COVID-19 immunization in her brief time at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Vaccine Program

Health officials were set to announce major changes to the childhood immunization program earlier this month, aligning the US with the Danish immunization schedule, sources say – a significant shift that would place the US at odds with much of the global community with insufficient data for benefit. The announcement has been postponed until the new year.

Instead of Vinay Prasad, Høeg is listed to speak at the gathering. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth individual to head the division this calendar year.

A Shift at the Regulatory Body

The acting appointment might represent a closer partnership between the pharmaceutical and vaccine branches as Dr. Høeg and Prasad solidify control at the FDA – and it signals a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

Høeg has often pushed for ending some childhood immunization guidelines in the US in order to be more similar to Denmark's approach, a country with universal health coverage and a citizenry about the size of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on vaccines – traditionally the domain of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Questions Over Expertise

Dr. Høeg has little discernible background in medication creation, regulation or leadership, which has been customary for former directors of the CBER. She has worked at the FDA as a key advisor to the FDA chief and CBER since March.

“She appears not to have the necessary background” for running the drug-regulation department, remarked Dr. Jonathan Howard. “She’s never run a scientific study. She is not versed in running a sizeable institution. She has no expertise in industry regulation.”

Former directors of CBER would “grasp laws and regulations and the research of pharmaceutical innovation”, commented a former acting FDA commissioner. “Frankly, she lacks the sort of resume that former directors who led CBER have had.”

CDER has an immense workload at the FDA, the former commissioner stated.

“Many people just focuses on the innovative therapies, but the generic program authorizes numerous off-brand pharmaceuticals. There’s a biosimilars division, over-the-counter program and more, and each of these must be looked after,” she explained. “The area you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a significant administrative aspect to the role, which manages in excess of 5,000 staff members. “It is a enormous leadership role, if you perform it correctly,” the former official concluded.

Official Statement and Controversial Initiatives

Regarding questions about Dr. Høeg's fitness for the role and whether this assignment represents more teamwork among FDA leaders on immunizations, a spokesperson said that the “inquiries rely on inaccurate assumptions”.

“Her experience is consistent with the duties of her job,” the official said, pointing to the months Høeg spent counseling the agency head on “medication safety and oversight research, including computerized risk analysis and immunization monitoring”.

As the temporary head, Høeg takes over the agency head's controversial priority voucher program, a controversial expedited medication authorization process that reportedly worried her former heads. “How are these medications being picked for this fast-track system? Who takes the decisions?” Dr. Howard said. “There is a lot of secrecy going on at the FDA right now.”

Broadly speaking, he stated, “the agency seems to be moving towards laxer oversight of all drugs, with the exception of immunizations.”

Public History on Immunizations

Regarding vaccines, Dr. Høeg has a clearer, if problematic, track record, critics have noted. She released a study using unverified crowd-sourced reports to determine the incidence of heart inflammation following COVID-19 immunization. She consulted for the state of Florida chief medical officer Joseph Ladapo, who was said to have changed statistics to imply COVID-19 vaccinations are more dangerous than they are.

Among her “desired changes” for the current administration encompassed revising rules for recently developed shots and ending “non-essential” immunizations, she remarked following the vote on a audio program. At the agency, Høeg has reportedly proposed excluding teenage boys from receiving Covid vaccines.

“She’s an thorough true believer who begins with her preconceived notions and works backwards to fit the science in a highly misleading, fraudulent manner,” Dr. Howard argued.

Consolidating Power and a “Push for Payback”

Høeg joined other contrarians, {like|